Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An optic atrophy that is caused by a mutation in the TMEM126A gene.
Features include sometimes findings: Strabismus, Thickened heart muscle (hypertrophic cardiomyopathy), Inner ear hearing loss (sensorineural hearing impairment), and Horizontal nystagmus. 12 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 5 | Strabismus, Visual impairment, Damage to the optic nerve (optic atrophy) |
TMEM126A function has not been fully characterized.
Autosomal recessive optic atrophy, OPA7 type is caused by mutations in the TMEM126A gene on chromosome 11.
Genetic testing for TMEM126A is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for autosomal recessive optic atrophy, OPA7 type has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for autosomal recessive optic atrophy, OPA7 type.
211 publications have been identified in PubMed for autosomal recessive optic atrophy, OPA7 type. Kisho has analyzed 95 by research type. Research spans Basic Science / Preclinical (40%), Review / Meta-Analysis (24%), and Case Report / Case Series (9%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 38 | 40% |
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 9:39 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Heart and blood vessels
1 |
Thickened heart muscle (hypertrophic cardiomyopathy) |
Ears | 1 | Inner ear hearing loss (sensorineural hearing impairment) |
Muscles | 1 | Damage to the optic nerve (optic atrophy) |
Age of onset: childhood.
Research summaries |
23 |
24% |
Patient case studies | 9 | 9% |
Disease patterns and progression | 9 | 9% |
Testing and diagnosis research | 6 | 6% |
New treatment approaches | 6 | 6% |
Clinical study results | 3 | 3% |
Other research | 1 | 1% |
Menden B (2026). [PMID: 41690933](https://pubmed.ncbi.nlm.nih.gov/41690933/). *Nat Commun*. [Review / Meta-Analysis]
Rocha Cabrero F (2026). [PMID: 32809697](https://pubmed.ncbi.nlm.nih.gov/32809697/). *Unknown Journal*. [Gene Therapy / Novel Therapeutics]
Patel BC (2026). [PMID: 28613618](https://pubmed.ncbi.nlm.nih.gov/28613618/). *Unknown Journal*. [Basic Science / Preclinical]
Koester KH (2026). [PMID: 41870100](https://pubmed.ncbi.nlm.nih.gov/41870100/). *Int Ophthalmol Clin*. [Review / Meta-Analysis]
Wong DCS (2026). [PMID: 41318849](https://pubmed.ncbi.nlm.nih.gov/41318849/). *Eye (Lond)*. [Review / Meta-Analysis]
Hall WA (2026). [PMID: 32809418](https://pubmed.ncbi.nlm.nih.gov/32809418/). *Unknown Journal*. [Epidemiology / Natural History]
Beaulieu C (2026). [PMID: 41954904](https://pubmed.ncbi.nlm.nih.gov/41954904/). *JAMA Ophthalmol*. [Epidemiology / Natural History]
Bai CW (2025). [PMID: 39543818](https://pubmed.ncbi.nlm.nih.gov/39543818/). *Aging Cell*. [Gene Therapy / Novel Therapeutics]
Szanto D (2025). [PMID: 40839281](https://pubmed.ncbi.nlm.nih.gov/40839281/). *JAMA Ophthalmol*. [Diagnostic / Biomarker]
Yao SQ (2025). [PMID: 40447565](https://pubmed.ncbi.nlm.nih.gov/40447565/). *Cell Death Discov*. [Basic Science / Preclinical]